{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:55:37Z","timestamp":1774641337239,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7491","license":[{"start":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T00:00:00Z","timestamp":1391558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T00:00:00Z","timestamp":1391558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2014,3,13]]},"DOI":"10.1038\/nature12966","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T12:26:05Z","timestamp":1391516765000},"page":"201-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":521,"title":["Proof of principle for epitope-focused vaccine design"],"prefix":"10.1038","volume":"507","author":[{"given":"Bruno E.","family":"Correia","sequence":"first","affiliation":[]},{"given":"John T.","family":"Bates","sequence":"additional","affiliation":[]},{"given":"Rebecca J.","family":"Loomis","sequence":"additional","affiliation":[]},{"given":"Gretchen","family":"Baneyx","sequence":"additional","affiliation":[]},{"given":"Chris","family":"Carrico","sequence":"additional","affiliation":[]},{"given":"Joseph G.","family":"Jardine","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Rupert","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Correnti","sequence":"additional","affiliation":[]},{"given":"Oleksandr","family":"Kalyuzhniy","sequence":"additional","affiliation":[]},{"given":"Vinayak","family":"Vittal","sequence":"additional","affiliation":[]},{"given":"Mary J.","family":"Connell","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Stevens","sequence":"additional","affiliation":[]},{"given":"Alexandria","family":"Schroeter","sequence":"additional","affiliation":[]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Skye","family":"MacPherson","sequence":"additional","affiliation":[]},{"given":"Andreia M.","family":"Serra","sequence":"additional","affiliation":[]},{"given":"Yumiko","family":"Adachi","sequence":"additional","affiliation":[]},{"given":"Margaret A.","family":"Holmes","sequence":"additional","affiliation":[]},{"given":"Yuxing","family":"Li","sequence":"additional","affiliation":[]},{"given":"Rachel E.","family":"Klevit","sequence":"additional","affiliation":[]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[]},{"given":"Richard T.","family":"Wyatt","sequence":"additional","affiliation":[]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[]},{"given":"Roland K.","family":"Strong","sequence":"additional","affiliation":[]},{"given":"James E.","family":"Crowe","sequence":"additional","affiliation":[]},{"given":"Philip R.","family":"Johnson","sequence":"additional","affiliation":[]},{"given":"William R.","family":"Schief","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,2,5]]},"reference":[{"key":"BFnature12966_CR1","volume-title":"Vaccines","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A., Orenstein, W. A. & Offit, P. A. Vaccines 6th edn (Elsevier, 2012)"},{"key":"BFnature12966_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nri3085","volume":"11","author":"R Rappuoli","year":"2011","unstructured":"Rappuoli, R., Mandl, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nature Rev. Immunol. 11, 865\u2013872 (2011)","journal-title":"Nature Rev. Immunol."},{"key":"BFnature12966_CR3","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095\u20132128 (2012)","journal-title":"Lancet"},{"key":"BFnature12966_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray, C. J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197\u20132223 (2012)","journal-title":"Lancet"},{"key":"BFnature12966_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209\u20132220 (2009)","journal-title":"N. Engl. J. Med."},{"key":"BFnature12966_CR6","doi-asserted-by":"crossref","unstructured":"The RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284\u20132295 (2012)","DOI":"10.1056\/NEJMoa1208394"},{"key":"BFnature12966_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028 (2013)","journal-title":"Lancet"},{"key":"BFnature12966_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","volume":"12","author":"MT Osterholm","year":"2012","unstructured":"Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia, E. A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 36\u201344 (2012)","journal-title":"Lancet Infect. Dis."},{"key":"BFnature12966_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507 (2013)","journal-title":"Nature"},{"key":"BFnature12966_CR10","doi-asserted-by":"publisher","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","volume":"31","author":"LJ Anderson","year":"2013","unstructured":"Anderson, L. J. et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31 (Suppl. 2). B209\u2013B215 (2013)","journal-title":"Vaccine"},{"key":"BFnature12966_CR11","unstructured":"U.S. Food and Drug Administration. Vaccines, Blood & Biologics http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/"},{"key":"BFnature12966_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nri891","volume":"2","author":"DR Burton","year":"2002","unstructured":"Burton, D. R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 706\u2013713 (2002)","journal-title":"Nature Rev. Immunol."},{"key":"BFnature12966_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1126\/science.1225416","volume":"337","author":"DR Burton","year":"2012","unstructured":"Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183\u2013186 (2012)","journal-title":"Science"},{"key":"BFnature12966_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"H Wu","year":"2007","unstructured":"Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652\u2013665 (2007)","journal-title":"J. Mol. Biol."},{"key":"BFnature12966_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nsmb.1723","volume":"17","author":"JS McLellan","year":"2010","unstructured":"McLellan, J. S. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nature Struct. Mol. Biol. 17, 248\u2013250 (2010)","journal-title":"Nature Struct. Mol. Biol."},{"key":"BFnature12966_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","volume":"18","author":"BE Correia","year":"2010","unstructured":"Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116\u20131126 (2010)","journal-title":"Structure"},{"key":"BFnature12966_CR17","doi-asserted-by":"publisher","first-page":"17880","DOI":"10.1073\/pnas.1004728107","volume":"107","author":"G Ofek","year":"2010","unstructured":"Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA 107, 17880\u201317887 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature12966_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","volume":"409","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853\u2013866 (2011)","journal-title":"J. Mol. Biol."},{"key":"BFnature12966_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1209368","volume":"334","author":"ML Azoitei","year":"2011","unstructured":"Azoitei, M. L. et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373\u2013376 (2011)","journal-title":"Science"},{"key":"BFnature12966_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jmb.2011.10.003","volume":"415","author":"ML Azoitei","year":"2012","unstructured":"Azoitei, M. L. et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J. Mol. Biol. 415, 175\u2013192 (2012)","journal-title":"J. Mol. Biol."},{"key":"BFnature12966_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1126\/science.1089427","volume":"302","author":"B Kuhlman","year":"2003","unstructured":"Kuhlman, B. et al. Design of a novel globular protein fold with atomic-level accuracy. Science 302, 1364\u20131368 (2003)","journal-title":"Science"},{"key":"BFnature12966_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11600","volume":"491","author":"N Koga","year":"2012","unstructured":"Koga, N. et al. Principles for designing ideal protein structures. Nature 491, 222\u2013227 (2012)","journal-title":"Nature"},{"key":"BFnature12966_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jmb.2010.09.061","volume":"405","author":"BE Correia","year":"2011","unstructured":"Correia, B. E. et al. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J. Mol. Biol. 405, 284\u2013297 (2011)","journal-title":"J. Mol. Biol."},{"key":"BFnature12966_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/infdis\/jiq100","volume":"203","author":"Q Zhu","year":"2011","unstructured":"Zhu, Q. et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab. J. Infect. Dis. 203, 674\u2013682 (2011)","journal-title":"J. Infect. Dis."},{"key":"BFnature12966_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/330381a0","volume":"330","author":"BE Clarke","year":"1987","unstructured":"Clarke, B. E. et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330, 381\u2013384 (1987)","journal-title":"Nature"},{"key":"BFnature12966_CR26","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1016\/S0264-410X(02)00266-9","volume":"20","author":"A Jegerlehner","year":"2002","unstructured":"Jegerlehner, A. et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104\u20133112 (2002)","journal-title":"Vaccine"},{"key":"BFnature12966_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/INF.0b013e318282603a","volume":"32","author":"HS Jafri","year":"2013","unstructured":"Jafri, H. S., Wu, X., Makari, D. & Henrickson, K. J. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr. Infect. Dis. J. 32, 335\u2013340 (2013)","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnature12966_CR28","doi-asserted-by":"publisher","first-page":"142ra196","DOI":"10.1126\/scitranslmed.3003752","volume":"4","author":"C Sundling","year":"2012","unstructured":"Sundling, C. et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci. Transl. Med. 4, 142ra196 (2012)","journal-title":"Sci. Transl. Med."},{"key":"BFnature12966_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nsmb.2250","volume":"19","author":"X Wen","year":"2012","unstructured":"Wen, X. et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nature Struct. Mol. Biol. 19, 461\u2013463 (2012)","journal-title":"Nature Struct. Mol. Biol."},{"key":"BFnature12966_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545\u2013574 (2011)","journal-title":"Methods Enzymol."},{"key":"BFnature12966_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0076-6879(04)83004-0","volume":"383","author":"CA Rohl","year":"2004","unstructured":"Rohl, C. A., Strauss, C. E., Misura, K. M. & Baker, D. Protein structure prediction using Rosetta. Methods Enzymol. 383, 66\u201393 (2004)","journal-title":"Methods Enzymol."},{"key":"BFnature12966_CR32","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/pro.458","volume":"19","author":"W Sheffler","year":"2010","unstructured":"Sheffler, W. & Baker, D. RosettaHoles2: a volumetric packing measure for protein structure refinement and validation. Protein Sci. 19, 1991\u20131995 (2010)","journal-title":"Protein Sci."},{"key":"BFnature12966_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/07391102.2000.10506570","volume":"17","author":"M Bansal","year":"2000","unstructured":"Bansal, M., Kumar, S. & Velavan, R. HELANAL: a program to characterize helix geometry in proteins. J. Biomol. Struct. Dyn. 17, 811\u2013819 (2000)","journal-title":"J. Biomol. Struct. Dyn."},{"key":"BFnature12966_CR34","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/nprot.2006.204","volume":"1","author":"NJ Greenfield","year":"2007","unstructured":"Greenfield, N. J. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nature Protocols 1, 2527\u20132535 (2007)","journal-title":"Nature Protocols"},{"key":"BFnature12966_CR35","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1038\/nprot.2006.229","volume":"1","author":"NJ Greenfield","year":"2007","unstructured":"Greenfield, N. J. Determination of the folding of proteins as a function of denaturants, osmolytes or ligands using circular dichroism. Nature Protocols 1, 2733\u20132741 (2007)","journal-title":"Nature Protocols"},{"key":"BFnature12966_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00197809","volume":"6","author":"F Delaglio","year":"1995","unstructured":"Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277\u2013293 (1995)","journal-title":"J. Biomol. NMR"},{"key":"BFnature12966_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF00404272","volume":"4","author":"BA Johnson","year":"1994","unstructured":"Johnson, B. A. & Blevins, R. A. NMR View: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 4, 603\u2013614 (1994)","journal-title":"J. Biomol. NMR"},{"key":"BFnature12966_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0264-410X(90)90253-I","volume":"8","author":"BR Murphy","year":"1990","unstructured":"Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S. M. & Prince, G. A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497\u2013502 (1990)","journal-title":"Vaccine"},{"key":"BFnature12966_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jim.2010.08.005","volume":"362","author":"M Chen","year":"2010","unstructured":"Chen, M. et al. A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J. Immunol. Methods 362, 180\u2013184 (2010)","journal-title":"J. Immunol. Methods"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature12966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature12966","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature12966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:48:26Z","timestamp":1733939306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature12966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,5]]},"references-count":39,"journal-issue":{"issue":"7491","published-print":{"date-parts":[[2014,3,13]]}},"alternative-id":["BFnature12966"],"URL":"https:\/\/doi.org\/10.1038\/nature12966","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718266858.793517825","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718266858.793492538","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718266858.793492244","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718266858.793499577","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,5]]},"assertion":[{"value":"1 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.R.S. owns shares in and is co-founder of a company (CompuVax, Inc.) that intends to develop vaccines for RSV and other pathogens based on epitope-focused immunogens pursuant to a research and license agreement in negotiation with The Scripps Research Institute.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}